Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.0K | $15.0K | $138K | $21.0K | $0.00 | — | — | — | — | — |
| Revenue growth | — | -21.1% | 820.0% | -84.8% | -100.0% | — | — | — | — | — |
| Operating income | -$9.02M | -$14.1M | -$7.36M | -$8.99M | -$8.79M | -$13.5M | -$11.5M | -$10.8M | -$7.39M | -$9.22M |
| Operating margin | -47447.4% | -93746.7% | -5336.2% | -42795.2% | — | — | — | — | — | — |
| Net income | -$8.99M | -$12.5M | -$7.36M | -$8.91M | -$8.79M | -$13.3M | -$11.5M | -$10.8M | -$7.15M | -$8.70M |
| Net margin | -47336.8% | -83013.3% | -5333.3% | -42419.0% | — | — | — | — | — | — |
| EPS (diluted) | -$16.41 | -$5.52 | -$57.46 | -$19.33 | -$1.92 | -$12.43 | -$10.10 | -$46.76 | -$9.08 | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.76M | -$9.51M | -$7.52M | -$8.64M | -$8.80M | -$11.9M | -$12.1M | -$10.7M | -$7.11M | -$7.98M |
| Capital expenditures | $4.00K | $203K | $5.00K | $72.0K | $19.0K | $51.0K | $121K | $5.00K | $1.00K | $12.0K |
| Free cash flow | -$7.76M | -$9.72M | -$7.53M | -$8.72M | -$8.82M | -$11.9M | -$12.3M | -$10.8M | -$7.11M | -$7.99M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $12.9M | $3.58M | $14.9M | $6.98M | $14.3M | $24.1M | $11.8M | $8.49M | $5.38M | $21.0M |
| Total assets | $13.4M | $4.10M | $15.3M | $8.04M | $15.7M | $25.2M | $12.8M | $9.36M | $5.74M | $21.5M |
| Total liabilities | — | — | $1.74M | $2.29M | $2.72M | $3.24M | $1.97M | $1.63M | $1.01M | $1.34M |
| Long-term debt | — | — | — | $0.00 | $231K | $0.00 | — | — | — | — |
| Shareholders' equity | $10.9M | $1.83M | $13.6M | $5.75M | $13.0M | $21.9M | $10.8M | $7.73M | $4.72M | $20.1M |
| Retained earnings | -$66.1M | -$78.6M | -$85.9M | -$94.8M | -$104M | -$117M | -$128M | -$139M | -$146M | -$155M |
| Shares (wtd avg diluted) | 1.30M | 2.43M | 343K | 669K | 5.78M | 1.07M | 1.14M | 232K | 787K | 5.98M |
Every figure is extracted from Phio Pharmaceuticals Corp.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.